Risk of reactivation of hepatitis B virus (HBV) and tuberculosis (TB) and complications of hepatitis C virus (HCV) following Tocilizumab therapy: A systematic review to inform risk assessment in the COVID era
Cori Campbell, Monique Andersson, View ORCID ProfileM Azim Ansari, Olivia Moswela, Siraj A Misbah, Paul Klenerman, View ORCID ProfilePhilippa C Matthews
doi: https://doi.org/10.1101/2021.03.22.21254128
Cori Campbell
1Nuffield Department of Medicine, University of Oxford, Medawar Building for Pathogen Research, South Parks Road, Oxford OX1 3SY, UK
Monique Andersson
2Department of Infectious Diseases and Microbiology, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Headley Way, Oxford OX3 9DU, UK
3Nuffield Department of Clinical Laboratory Sciences, University of Oxford, Headley Way, Oxford OX3 9DU
M Azim Ansari
1Nuffield Department of Medicine, University of Oxford, Medawar Building for Pathogen Research, South Parks Road, Oxford OX1 3SY, UK
4Wellcome Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford, OX3 7BN
Olivia Moswela
5Pharmacy Department, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Headley Way, Oxford OX3 9DU, UK
Siraj A Misbah
6Department of Clinical Immunology, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Headley Way, Oxford OX3 9DU, UK
Paul Klenerman
1Nuffield Department of Medicine, University of Oxford, Medawar Building for Pathogen Research, South Parks Road, Oxford OX1 3SY, UK
2Department of Infectious Diseases and Microbiology, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Headley Way, Oxford OX3 9DU, UK
Philippa C Matthews
1Nuffield Department of Medicine, University of Oxford, Medawar Building for Pathogen Research, South Parks Road, Oxford OX1 3SY, UK
2Department of Infectious Diseases and Microbiology, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Headley Way, Oxford OX3 9DU, UK
Data Availability
All data presented were extracted from published articles identified via systematic review.
Posted March 26, 2021.
Risk of reactivation of hepatitis B virus (HBV) and tuberculosis (TB) and complications of hepatitis C virus (HCV) following Tocilizumab therapy: A systematic review to inform risk assessment in the COVID era
Cori Campbell, Monique Andersson, M Azim Ansari, Olivia Moswela, Siraj A Misbah, Paul Klenerman, Philippa C Matthews
medRxiv 2021.03.22.21254128; doi: https://doi.org/10.1101/2021.03.22.21254128
Risk of reactivation of hepatitis B virus (HBV) and tuberculosis (TB) and complications of hepatitis C virus (HCV) following Tocilizumab therapy: A systematic review to inform risk assessment in the COVID era
Cori Campbell, Monique Andersson, M Azim Ansari, Olivia Moswela, Siraj A Misbah, Paul Klenerman, Philippa C Matthews
medRxiv 2021.03.22.21254128; doi: https://doi.org/10.1101/2021.03.22.21254128
Subject Area
Subject Areas
- Addiction Medicine (365)
- Allergy and Immunology (685)
- Anesthesia (183)
- Cardiovascular Medicine (2724)
- Dermatology (234)
- Emergency Medicine (411)
- Epidemiology (12378)
- Forensic Medicine (10)
- Gastroenterology (783)
- Genetic and Genomic Medicine (4233)
- Geriatric Medicine (394)
- Health Economics (698)
- Health Informatics (2732)
- Health Policy (1014)
- Hematology (369)
- HIV/AIDS (874)
- Medical Education (404)
- Medical Ethics (111)
- Nephrology (450)
- Neurology (4010)
- Nursing (216)
- Nutrition (594)
- Oncology (2114)
- Ophthalmology (602)
- Orthopedics (251)
- Otolaryngology (310)
- Pain Medicine (256)
- Palliative Medicine (77)
- Pathology (475)
- Pediatrics (1145)
- Primary Care Research (465)
- Public and Global Health (6630)
- Radiology and Imaging (1440)
- Respiratory Medicine (883)
- Rheumatology (418)
- Sports Medicine (350)
- Surgery (461)
- Toxicology (57)
- Transplantation (192)
- Urology (171)